Avalo Therapeutics (AVTX) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $35.00 | Aug 7, 2026 |
| Guggenheim | Maintained | Buy | $48.00 from $50.00 | Aug 7, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $38.00 | Jul 6, 2026 |
| BTIG | Maintained | Buy | $58.00 | Jun 16, 2026 |
| B of A Securities | Initiated Coverage | Buy | $35.00 | Jun 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 from $40.00 | May 14, 2026 |
| Mizuho | Maintained | Outperform | $45.00 from $39.00 | May 14, 2026 |
| Wedbush | Maintained | Outperform | $34.00 from $40.00 | May 14, 2026 |
| Citizens | Maintained | Market Outperform | $55.00 from $62.00 | May 14, 2026 |
| Piper Sandler | Maintained | Overweight | $60.00 from $48.00 | May 11, 2026 |
| BTIG | Maintained | Buy | $58.00 from $40.00 | May 6, 2026 |
| Wedbush | Maintained | Outperform | $40.00 from $29.00 | May 6, 2026 |
| Citizens | Maintained | Market Outperform | $62.00 from $52.00 | May 6, 2026 |
| BTIG | Maintained | Buy | $40.00 | Apr 13, 2026 |
| Wolfe Research | Initiated Coverage | Outperform | $48.00 | Apr 9, 2026 |
| Citizens | Initiated Coverage | Market Outperform | $52.00 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $25.00 | Mar 25, 2026 |
| BTIG | Maintained | Buy | $40.00 | Mar 24, 2026 |
| Guggenheim | Initiated Coverage | Buy | $50.00 | Feb 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Jan 15, 2026 |
Frequently asked questions
Is AVTX a buy, sell, or hold?
Analysts covering Avalo Therapeutics currently average a Buy rating: 13 buy, 0 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on AVTX?
On Aug 7, 2026, HC Wainwright & Co. maintained Avalo Therapeutics at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.